1. Supplementary Figure 1 A B C siControl siRNF31 siRNF31+siP53 siControl
G2-M: 23.2%
G1:76.7%
S: 7.5%
G2-M: 15.9%
G1:66.5%
S: 15.6%
G2-M: 18.3% B
siControl
siRNF31
siRNF31+siP53 C
siControl
siRNF31
siRNF31+siP53

2. Supplementary Figure 2 A B * Relative cell viability Cisplatin
siControl
siRNF31
siRNF31+siP53
Vehicle
Cisplatin
3.5%
3.7%
12.5%
18.5%
11.5%

3. Supplementary Figure 3 Empty Vector P53 overexpression
Sub-G1 phase(Percentage)
12.4±0.1
10.4±0.3

4. Supplementary Figure 4 A B Vehicle Nutlin-3 Relative mRNA expression *